Safety and efficacy of intra-articular anti-tumor necrosis factor \u3b1 agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare by Carubbi, F. et al.
International Journal of 
Immunopathology and Pharmacology
 1 –15
© The Author(s) 2015





Despite growing progress in the treatment of articu-
lar chronic inflammatory disorders, refractory 
mono-oligo-arthritis is still a common clinical 
problem. In this case, therapeutic approach is rather 
complex, often requiring the combination of sys-
temic non-steroid anti-inflammatory drugs 
(NSAIDs) and local corticosteroid administration. 
Unfortunately, the outcome of pharmacological 
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Abstract
The aim of this study was to assess safety and efficacy of ultrasonography (US)-guided intra-articular injections using 
tumor necrosis factor (TNF) blockers compared to corticosteroids in rheumatoid arthritis (RA) or psoriatic arthritis 
(PsA) patients, experiencing refractory monoarthritis despite the current systemic therapy. Eighty-two patients were 
randomized to receive three intra-articular injections monthly of either corticosteroid or TNF blockers. Primary 
endpoints were the safety and an improvement greater than 20% for visual analogic scales of involved joint pain in 
patients injected with anti-TNFα. Further clinical, US, and magnetic resonance imaging (MRI) evaluations were considered 
secondary endpoints. Intra-articular TNF blockers are a safe strategy, determining a significant reduction of patient and 
physician reported clinical outcomes and US/MRI scores, in RA and PsA patients, when compared to intra-articular 
injections of corticosteroids. US guidance excluded the possibility to inject the drug in the wrong site, maximizing local 
effects, reducing systemic effects, and increasing the safety of the procedure. Patients with inflammatory monoarthritis 
could be successfully treated with US-guided intra-articular TNF blockers that are a safe and well tolerated procedure, 
to achieve a longstanding clinical and radiological good clinical response and/or disease remission.
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treatment is often poor and weighted by adverse 
events, therefore surgical procedures including syn-
oviectomy and joint replacement might be required.1 
Indeed, persistent monoarthritis may be a debilitat-
ing and destructive condition as a consequence of 
both inflammatory-related joint destruction and 
secondary osteoarthritis. Tumor necrosis factor α 
(TNFα) emerged as a potent pro-inflammatory 
mediator in the pathogenesis of inflammatory arth-
ritides. TNFα is was found in the synovial tissue 
and cartilage-pannus junctions in patients with 
rheumatoid arthritis (RA) or psoriatic arthritis 
(PsA). TNFα is involved in cartilage and bone tis-
sue degradation and in the modulation of joint 
pain.2–4 Moreover, TNFα in synovium correlates 
with disease activity in patients with RA5 and may 
directly regulate angiogenetic mechanisms.6 
Overexpression of TNFα is believed to play a key 
role in the pathogenic mechanisms linking psoriasis 
and arthritis, mediating a number of biological pro-
cesses that can result in joint damage characterized 
by stimulation of bone resorption and inhibition of 
bone formation and of synthesis of proteoglycans. 
TNFα may also contribute to vascular proliferation, 
which is probably one of the key and earlier observ-
able changes in psoriasis and PsA.7
On this background, TNFα antagonists cur-
rently represent a widely and effective employed 
therapeutic approach in chronic arthritides.8,9 
Although systemic anti-TNFα treatment offers 
considerable improvement in systemic inflamma-
tory joint diseases, many patients still experience 
persistent symptoms in a single or few joints. An 
insufficient level of drug in the inflamed joints has 
been suggested as possible explanation and intra-
articular injections of corticosteroid is a well-
established treatment to overcome this problem.10 
On this basis, the association of systemic and intra-
articular TNFα blockers could allow to achieve a 
better clinical response. In recent years several 
studies were published concerning the use of intra-
articular anti-TNFα agents to treat refractory 
monoarthritis. However only conflicting results 
are available in literature.11–22 At present, both 
magnetic resonance imaging (MRI) and ultra-
sonography (US) are established methods to evalu-
ate the severity of monoarthtitis flares in these 
conditions;23–26 furthermore, US improves the per-
formance of intra-articular injections overcoming 
technical problems such as the correct position of 
the needle and the aspiration of joint effusion.27 In 
fact it is well know that only in 50% of intra-artic-
ular injections is the drug placed in the right place 
and this strongly decreases the efficacy of these 
procedures.28
The aim of this randomized, controlled, single-
blinded study was to assess the safety and efficacy 
of US-guided intra-articular injection using TNF 
blockers compared to corticosteroids in patients 
with RA or PsA, experiencing refractory monoar-
thritis. US scan was employed in the study both to 
guide intra-articular injections assessing the joint 
clinical response by validated methods, where pos-
sible, and observing the structural modification in 
the joint where we do not still have validated meas-
ures. MRI was employed in addition to US in 
patients with RA to evaluate the clinical response 
by validated measures in wrist and metacar-
pophalangeal joints during the follow-up.23,29–31
Materials and methods
Study groups and US-guided injections
Eighty-two consecutive patients referring to the 
Rheumatology Unit, University of L’Aquila, Italy 
were included in the study; seven patients, assessed 
for eligibility, declined to participate. Of these, 41 
patients were affected by RA and 41 by PsA. All 
patients were aged over 18 years, fulfilled the cri-
teria for RA32 or for PsA33 and were receiving sta-
ble doses of an anti-TNFα agent (infliximab, 
etanercept, adalimumab) in combination with one 
or more disease modifying anti-rheumatic drugs 
(DMARDs) for at least 3 months. The inclusion 
criteria for the study was the clinical evidence of a 
persistent arthritis despite the aforementioned ther-
apy or a new single joint arthritis (shoulder, elbow, 
wrist, metacarpophalangeal joint, proximal inter-
phalangeal joint, hip, or knee). We did not consider 
distal interphalangeal joints eligible for local treat-
ment, due to the lack of synovial tissue.
After informed consent in accordance with the 
Declaration of Helsinki, patients were randomized 
to receive one intra-articular injection each month 
for 3 consecutive months of either corticosteroid 
(triamcinolone 40 mg) or an anti-TNFα agent (inf-
liximab 100 mg; etanercept 50 mg; adalimumab 40 
mg). In the latter cases, patients were injected with 
the same anti-TNFα agent that they were receiving 
systemically. During the study period, systemic 
therapy with anti-TNFα agents and DMARDs was 
maintained stable. Patients were not allowed to 
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increase their oral prednisolone therapy. The whole 
study was approved by the local Ethics Committee 
and performed according to Good Clinical Practice 
guidelines. The study was randomized, stratified 
by the underlying disease and the type of joint with 
a pre-given code of randomization from an exter-
nal observer. The allocation to one of two treat-
ment groups was based on a permuted block 
randomization list. A study clinician, collaborated 
with the external observer, performed the randomi-
zation, and prepared a syringe. All calculations of 
data were performed before breaking the code. 
US-guided intra-articular injections were per-
formed at baseline, week 4, and week 8. US was 
used to determine the placement of the syringe 
prior to and during aspiration and injection into the 
joint cavity. The measure of needle (from 20G for 
shoulder to 27G for proximal interphalangeal joint) 
and the amount of injected drug was chosen on the 
basis of joint type. In particular, intra-articular inf-
liximab was injected at the following dosages: 100 
mg/10 mL for the knee, shoulder, and hip; 50 mg/5 
mL for elbow and wrist; and 10 mg/1 mL for meta-
carpophalangeal joint. Intra-articular etanercept 
was injected at a dosage of 50 mg/1 mL for all the 
treated joints; intra-articular adalimumab 40 
mg/0.8 mL was injected at a dosage of 50 mg/1 mL 
for all the treated joints; intra-articular triamci-
nolone was injected at a dosage of 40 mg/1 mL for 
all the treated joints. A 10 cc syringe, prefilled with 
the drug, was covered with an obscuring sleeve so 
that the patient could not detect which was being 
administered.
Primary endpoints
The primary endpoints of this study were: (1) the 
evaluation of intra-articular anti-TNFα injection 
safety compared to corticosteroid; (2) a 20% or 
greater improvement on visual analogic scales for 
involved joint pain (jVAS) in patients injected 
with anti-TNFα compared to patients injected 
with corticosteroid. Patients were evaluated at the 
time of the first injection and then at weeks 4, 8, 
12, and 24. For safety evaluation, the follow-up 
period was extended to week 52. Patients were 
asked about systemic or local adverse event occur-
rence at each visit that could be related to the 
injective procedure. Adverse events included local 
or systemic infection, allergy (cutaneous or res-
piratory), hyperglycemia, arterial hypertension, 
and headache. Adverse events were judged as seri-
ous if they resulted in death, were life-threatening 
according to the investigator’s own judgment, 
caused hospital admission, resulted in birth defect 
(from unplanned pregnancies) or disability, or 
were important medical events that could have 
jeopardized the patient or needed intervention to 
prevent another serious adverse event, or both.
Clinical evaluation and secondary endpoints
Patients were evaluated at baseline, at weeks 4, 8, 
and 12, and after 12 weeks from the last injection 
(week 24) for the evaluation of secondary end-
points, chosen among validated clinical and instru-
mental measures. The following self-reported 
outcomes on visual analogic scales (VAS) were 
employed both in RA and PsA patients: global pain 
(gVAS), Patient Global Assessment (GA) of 
Disease Activity, Global Health (GH) Status; 
Health Assessment Questionnaire (HAQ) was also 
completed at each time point. An independent cli-
nician, provided the degree of Physician-GA by 
VAS. Tender and swollen joints (Tj and Sj) were 
graded in the range of 0–3, with 0 = no activity and 
3 = most prominent activity. Erythrocyte sedimen-
tation rate (ESR, mm/h) and C-reactive protein 
(CRP, mg/L) were also recorded. Disease Activity 
Score on 28 joints (DAS28), using ESR, and 
Clinical Disease Activity Index (CDAI) were also 
calculated, both in RA patients and PsA patients, 
following the report that DAS28 has been vali-
dated for use in PsA.34,35
Clinical follow up at week 52 was performed in 
order to identify diseases flares in the injected 
joint. To this aim, we reported only new-onset 
arthritis in the joint treated with intra-articular anti-
TNFα or corticosteroid. In order to avoid any 
biases, we did not assess all other clinical parame-
ters employed at baseline to week 24, because of 
these data could be affected by other conditions 
such as arthritis involving different joints, extra-
articular manifestations (enthesitis, dactylitis), 
infectious diseases, and increase of ERS and CRP 
not related to rheumatic flares.
Magnetic resonance imaging
Contrast-enhanced MRI was performed, for tech-
nical reasons, at baseline and at week 12 only 
for RA patients with metacarpophalangeal joint 
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(13 patients) or wrist (11 patients) monoarthritis. 
All MRI examinations were performed using a 0.25 
T musculoskeletal dedicated scanner (G-scan, 
Esaote Biomedica, Genoa, Italy). Application of 
MRI sequences and use of intravenous injection of 
gadolinium-DTPA (Magnevist, Schering AG, 
Berlin, Germany) was performed as described else-
where.23 Synovitis, bone erosion, and bone edema 
were assessed according the EULAR–OMERACT 
RA MRI reference image atlas29,30 and disease 
activity was scored according the OMERACT RA 
MRI score (OMERACT RAMRIS).23,31
Ultrasonography
US examination was performed at baseline and 4 
weeks after each intra-articular injection (at weeks 4, 
8, and 12). Grayscale, B-mode, and power Doppler 
(PD) evaluation were performed with a ESAOTE 
MyLab70 (Esaote, Genova, Italy) with a linear trans-
ducer at 7–13 MHz. For B-Mode a frequency of 11 
MHz was used. PD settings were as follows: fre-
quency, 7 MHz; repetition frequency, 1 kHz at low 
filter wall (150 Hz). The color gain was set at the 
level at which noise artifacts appeared and gradually 
reduced, until only a flow signal, if present, was left. 
Synovial hypertrophy and synovial effusion were 
evaluated on two axes, longitudinal and transverse; 
the color-power Doppler was used to demonstrate, 
by evaluating the vascularity, the entity of synovial 
inflammation. US scan of the inflamed joint was per-
formed by the same specialist, an arbitrary scoring 
system for assessment of inflamed joint was applied 
considering synovial hypertrophy (0–3), joint effu-
sion (0–3), and PD evaluation (0–3).24–26,36–42
Statistical analysis
Our study was powered to detect a 20% difference 
in efficacy, regarding jVAS, in favor of anti-TNFα 
injection versus corticosteroid injection (α = 0.05, 
ß = 0.2) and SD calculated based on literature 
data,13,18,21 with 20 patients in each group. All data 
were analyzed by intention-to-treat analysis. 
Statistical analysis was performed with Graph-Pad 
5.0 software. One-way analysis of variance and 
multiple comparison post hoc tests were employed 
to calculate differences between baseline and fol-
lowing time points. Differences between the two 
treatment arms, small and large joints involvement, 
in both intra-articular corticosteroid and intra-
articular anti-TNFα group were tested with 
non-parametric Mann-Whitney U test. P values 
less than 0.05 were considered significant.
Results
Study groups, baseline demographic, and 
clinical characteristics
Demographic characteristics of patients are sum-
marized in Table 1. Eighty-two patients completed 
the observation period of 52 weeks (Figure 1). The 
study was approved in 2009 and recruitment ended 
in 2013.
Primary endpoints
In both treatment groups, no adverse events, with 
the exception of temporary local soreness after intra-
articular injection, were reported during the study. 
Intra-articular anti-TNFα injections were generally 
well-tolerated and no increased local pain, signs of 
infection or any other local or systemic reaction 
were observed. No adverse events judged by the 
investigator to be possibly, probably, or definitely 
related to intra-articular anti-TNFα injection were 
observed in the 52-week follow-up period.
The results at each time point, inside the four 
experimental groups, of visual analogic scales for 
involved joint pain (jVAS) are shown in Figure 2a. 
RA patients treated with intra-articular anti-TNFa 
agent reported much lower values of jVAS with 
respect to those treated with intra-articular corti-
costeroid at any time point expressed. This signifi-
cant reduction of jVAS, starting from week 4, was 
maintained over time (percentage of jVAS reduc-
tion, compared to baseline ± SEM, in anti-TNFα 
vs. corticosteroid group at week 4: 57.6 ± 3.93 vs. 
21.2 ± 7.59, P <0.001; at week 8: 73.9 ± 3.30 vs. 
33.5 ± 8.97, P <0.0001; at week 12: 75.4 ± 2.93 
vs. 35.6 ± 8.86, P <0.0001; at week 24: 73.8 ± 
3.43 vs. 35.5 ± 8.54, P <0.001, respectively). 
Similar results were observed in PsA patients 
treated with intra-articular anti-TNFα agent, when 
compared with PsA patients treated with with 
intra-articular corticosteroid (percentage of jVAS 
reduction, compared to baseline ± SEM, in anti-
TNFα vs. corticosteroid group at week 4: 55.9 ± 
4.68 vs. 20.3 ± 10.20, P <0.05; at week 8: 73.9 ± 
3.81 vs. 30.5 ± 10.53, P <0.001; at week 12: 74.5 
± 3.51 vs. 32.4 ± 10.26, P <0.001; at week 24: 
73.1 ± 4.34 vs. 33.2 ± 9.84, P <0.01, 
respectively).
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Secondary clinical outcomes
The modification at each time point, inside the four 
experimental groups, of the selected outcome meas-
ures is shown in Figures 2 and 3. A reduction of 
global pain was reported by all patients. Interestingly, 
while in patients treated with corticosteroids, such a 
decrease was stable over time with no further reduc-
tion after week 4, in anti-TNFα-treated patients we 
observed a stronger improvement, over time, of 
global pain. This result was confirmed by the evi-
dence of a statistically significant difference in the 
two treatment groups starting from week 8 (Figure 
2b). In anti-TNFα-treated patients, affected by RA, 
we observed a significant improvement of global 
outcomes, including Patient-GA and HAQ, and 
such a reduction was more pronounced with respect 
to that observed in patients treated with corticoster-
oids. Furthermore, no difference in Patient-GA and 
HAQ reduction according to intra-articular treat-
ment was observed in patients with PsA (Figure 2c, 
e). Concerning GH, a significant improvement was 
observed in all patients starting from week 4 but no 
further increase could be detected overtime (Figure 
2d). In RA patients, GH was significantly higher 
after intra-articular anti-TNFα treatment compared 
to patients treated with corticosteroids starting from 
week 8. Conversely, in PsA patients, no difference 
in GH assessment was observed in the two treat-
ment groups. In our study, an overall improvement 
of Tj score and Sj score was observed in RA patients 
treated with anti-TNFα, starting from week 4, and 
such improvements were more pronounced when 
compared to patients treated with corticosteroids at 
each time point. Conversely in PsA both anti-TNFα 
and corticosteroid treatment were comparable in 
the first 4 weeks (Figure 2f, g). Similar data were 
obtained regarding Physician-GA (Figure 2h). As 
expected, we failed to observe any difference in 
ESR and CRP values following intra-articular anti-
TNFα or corticosteroid treatment for both RA and 
PsA patients (data not shown). Finally, a reduction 
of DAS28 was also found in all patients and this 
reduction was confirmed at 24 weeks of follow-up, 
in both treatment groups. Of note, all RA patients 
with DAS28 ⩾2.6, and treated with intra-articular 
anti-TNFα agent, quickly achieved remission 
(DAS28 <2.6) at week 4. On the contrary, this was 
not observed in the intra-articular corticosteroid 
group which needed at least 8 weeks to achieve 
clinical remission. Regarding clinical remission in 
PsA patients, we failed to observe any significant 
difference in the two treatment arms (Figure 3b, c). 
Table 1. Demographic and clinical characteristics of patient cohort.









Age, median (range) (years) 48.2 (34–73) 49.6 (38–71) 44.3 (31–68) 41.6 (33–62)
Patients (female/male) 21 (15/6) 20 (15/5) 21 (11/10) 20 (13/7)
Disease duration, median (range) (years) 7.5 (0.8–19) 8.3 (0.9–21) 8.2 (0.9–17) 8.8 (1.3–19)
Joint, n (INF/ETA/ADA)  
Shoulder 1 1 (1/0/0) 2 2 (1/0/1)
Elbow 1 1 (0/1/0) 3 4 (1/2/1)
Wrist 6 5 (2/1/2) 2 2 (0/1/1)
MCP 6 7 (1/4/2) 4 3 (0/1/2)
PIP 2 1 (0/0/1) 0 0 (0/0/0)
Hip 1 1 (1/0/0) 4 3 (1/0/2)
Knee 4 4 (2/1/1) 6 6 (3/2/1)
Systemic anti-TNFα, number of patients 
(INF/ETA/ADA)
21 (8/6/7) 20 (7/7/6) 21 (7/6/8) 20 (6/6/8)
Single DMARD, number of patients (MTX/
LEF/CsA/SSZ/HCQ)
8 (5/3/0/0/0) 9 (7/2/0/0/) 9 (6/0/3/0/0) 8 (7/0/1/0/0)
Combined DMARDs, number of patients 
(MTX/LEF/CsA/SSZ/HCQ)
13 (7/4/6/2/8) 11 (7/4/3/0/9) 12 (8/3/5/8/0) 12 (9/2/6/7/0)
Systemic corticosteroids, number of patients 18 17 14 12
ADA, adalimumab; CsA, ciclosporin; DMARDs, disease-modifyingantirheumaticdrugs; ETA, etanercept; HCQ, hydroxychloroquine; INF, infliximab; 
LEF, leflunomide; MTX, methotrexate; MCP, metacarpophalangeal joint; PIP, proximalinterphalangeal joint; SSZ, sulfasalazine.
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In order to identify whether the changes in DAS28 
were independent on changes in the acute phase 
response, CDAI was also performed. A significant 
reduction of CDAI was observed in any experimen-
tal groups independently on the treatment and the 
underlying disease, but this improvement was more 
significant in patients treated with intra-articular 
anti-TNF agents (Figure 3a). Interestingly in RA 
patients who received intra-articular anti-TNFα 
agents, we observed a consistent decrease in the 
need of systemic corticosteroids that was signifi-
cantly more pronounced compared to those patients 
receiving intra-articular corticosteroids at any time. 
Concerning PsA patients such difference was evi-
dent only at weeks 4 and 8 (Figure 3d). In this set-
ting, a consistent reduction of NSAIDs intake was 
also reported from all patients independently on 
intra-articular treatment and underlying disease 
(Figure 3e).
To note, in the 52 weeks follow-up, no new flare 
of disease in the injected joint was observed in RA 
or PsA patients treated with intra-articular anti-
TNFα. On the contrary, in the RA and PsA group 
treated with intra-articular corticosteroids, five 
(24%) and seven (33%) new flares were recorded, 
respectively.
Ultrasonography
In the course of the study, US scan was performed 
both to assess peculiar features of either rheuma-
toid or seronegative synovitis and to guide intra-
articular injections. In this setting, semi-quantitative 
scores were calculated by an expert radiologist at 
Patients assessed for eligibility 
(n=89)
Excluded (n=7)
-Declined to participate (n=7)
Analysed (20 RA patients and 20 PsA patients)
-Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to receive intra-articular anti-TNFα
(20 RA patients and 20 PsA patients)
-Received allocated intervention (n=40)
-Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to received intra-articular corticosteroids
(21 RA patients and 21 PsA patients)
-Received allocated intervention (n=42)
-Did not receive allocated intervention (n=0)
Analysed (21 RA patients and 21 PsA patients)
-Excluded from analysis (n=0)
Patients randomized (n=82; 41 RA and 41 PsA patients)
Figure 1. Flow-chart of patients in this study.
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baseline, weeks 4, 8, and 12. A global reduction of 
both US synovial membrane thickening score, US 
joint effusion score, and PDUS score were observed 
in all treatment groups. Interestingly, such a 
decrease was much evident in anti-TNFα-treated 
patients when compared to patients treated with 
corticosteroids of both disease groups at each time 
point (Figures 3f–h and 4).
Comparison between small and large joints in 
RA patients
We subdivided RA patients into two groups accord-
ing to the injected joint (small vs. large), in order to 
identify any differences in clinical and US scores. 
Concerning clinical outcomes (jVAS, gVAS), the 
percentage of improvement at each time point 
Figure 2. The results of primary endpoint and clinical outcomes, in RA and PsA groups, are shown. The primary endpoint of the 
study was (a) Visual Analogic Scale for involved joint pain (jVAS); (b) gVAS, Visual Analogic Scale for global pain; (c) Patient-GA, 
Patient Global Assessment; (d) GH, Global Health Status; (e) HAQ, Health Assessment Questionnaire; (f) Tj, Tender joint score; 
(g) Sj, Swollen joint score; (h) Physician-GA, Physician Global Assessment. Bars in the line charts indicate mean ± SEM. Inside the 
box below the chart symbols refer to the comparison between each time point and the baseline according to the treatment arm 
(° p<0.001; § p<0.01; # p<0.05). ***p<0.001; **p<0.01 and *p<0.05 inside the chart refer to the comparison between the two 
treatment arms at the corresponding time point. CS, corticosteroids; TNFα, tumor necrosis factor α.
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compared to baseline, in the anti-TNFα-injected 
RA patients, was statistically significant in large 
joints but not in small joints (Figure 5a, b). 
Moreover, a significant improvement was observed 
in US joint effusion score only in large joints 
injected with anti-TNFα at weeks 4 and 8 in RA 
patients (Figure 5c–e). To note a similar trend was 
observed in the large joints of PsA patients but no 
statistical analysis was performed due to the low 
number of patients with small joints involvement 
(data not shown).
Magnetic resonance imaging
In selected RA patients, MRI scan was also per-
formed at baseline and week 12 to calculate vali-
dated scores for specific joints (wrist and MCP), 
including the MRI synovitis score, the MRI bone 
Figure 3. The results of clinical outcomes and US scores, in RA and PsA groups, are shown. (a) CDAI, Clinical Disease Activity 
Index; (b) DAS28, Disease Activity Score on 28 joints; (c) DAS28 ⩾2.6; (d) the mean dosage of systemic corticosteroids; (e) the 
daily use of NSAIDs, Non-Steroid Anti-Inflammatory Drugs; (f) the US synovial membrane thickening score; (g) the US joint effusion 
score; (h) the power Doppler US score (PDUS). Bars in the line charts indicate mean ± SEM. Inside the box below the chart 
symbols refer to the comparison between each time point and the baseline according to the treatment arm (° P <0.001; § P <0.01; 
# P <0.05). ***P <0.001; **P <0.01; and *P <0.05 inside the chart refer to the comparison between the two treatment arms at the 
corresponding time point. CS, corticosteroids; TNFα, tumor necrosis factor α; US, ultrasonography.
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erosion score, and the MRI bone edema score. We 
observed a statistically significant reduction of 
both MRI synovitis and bone edema scores in RA 
patients injected with either an anti-TNF agent or 
with corticosteroids. Interestingly, the reduction of 
MRI synovitis score in patients injected with anti-
TNFα was significantly more evident when com-
pared with the corticosteroid injected group. 
Conversely, no differences in MRI bone erosion 
score were observed probably due to the short time 
between the observations (Figure 6).
Discussion
To our knowledge, this is the first randomized, 
controlled, single-blinded study performed in a 
large cohort of patients with RA and PsA suffering 
with monoarthritis despite systemic therapy with 
anti-TNFα agent and DMARDs. We performed a 
52-week follow-up to address the safety and effi-
cacy of US-guided joint injections of anti-TNFα 
agents compared with corticosteroids to treat 
inflammatory monoarthritis by using both clinical 
and instrumental validated measures.
TNFα is a significant cytokine that mediates 
inflammation in RA and PsA. Elevation of TNFα 
levels have been observed in synovial fluid and the 
synovium of patients with RA or PsA, playing a 
central role in driving inflammation and bone deg-
radation.43 Due to its influence on various cells in 
synovial membrane, such as synoviocytes, mac-
rophages, chondrocytes, and osteoclasts, which are 
able to produce metalloproteinases, collagenase, 
and stromelysin, TNFα induces local inflammation 
and pannus formation, eventually leading to further 
erosion of cartilage and bone destruction.44 
Introduction of TNFα inhibitors has revolutionized 
RA and PsA treatment options resulting in the 
development of further biologic DMARDs.8,45 The 
effects of a TNFα blockade are partially dependent 
on synovial TNFα expression and infiltration by 
TNFα-producing inflammatory cells.5,46
In chronic and recurrent arthritis, inflammation 
and synovial tissue hyperplasia lead to joint dam-
age, pain, and loss of function. Currently, intra-
articular corticosteroids are the first line therapy;10,47 
however, their efficacy is rather varying. More 
than 50% of patients experience relapses within 6 
months after injection.48,49 An alternative local 
therapy, such as radiation synovectomy, did not 
show better results when compared to intra-articu-
lar corticosteroids in patients with recurrent knee 
arthritis.50 Several studies concerning the use of 
intra-articular anti-TNFα agents have been pub-
lished so far but results are not conclusive, with a 
wide range of clinical response and differences in 
the study design.11–22
In our study, intra-articular anti-TNFα injec-
tions were generally well-tolerated and no local or 
systemic reaction were observed. Furthermore, US 
guidance excluded the possibility to inject the drug 
in the wrong site, maximizing local effects, reduc-
ing systemic effects, and increasing the safety of 
the procedure.27,28 Intra-articular injections of anti-
TNFα agents determined a significant reduction of 
jVAS in both RA and PsA patients, achieving a 
20% difference in efficacy versus corticosteroid 
injection strategy, starting from week 4 and this 
effect was maintained overtime.
As far as the other clinical outcomes in RA 
patients are concerned, we demonstrated a statisti-
cally significant improvement of gVAS, 
Patient-GA, HAQ, GH, Physician-GA, Tj, and Sj 
scores in the anti-TNFα-injected group when 
compared to the corticosteroid-injected group. Of 
note, good clinical response was achieved rapidly 
(week 4) and maintained over time. A similar trend 
was observed in PsA patients, although we failed 
to reach significance between anti-TNFα- and 
Figure 4. Ultrasonography imaging of wrist joints of patients 
with RA injected with intra-articular anti-TNFα agent (a, c, e) 
and intra-articular corticosteroid (b, d, f). Both anti-TNFα and 
corticosteroid treatment determine a progressive reduction 
of joint effusion (arrow) but reduction of synovial membrane 
thickness (arrowhead) is more expressed in intra-articular anti-
TNFα group.
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corticosteroid-injected groups for gVAS, 
Patient-GA, HAQ, and GH, probably because 
inflammatory back pain, enthesitis, or skin psoria-
sis might affect global subjective clinical out-
comes.51 However, the reduction of Physician-GA, 
was statistically significant in the anti-TNF group 
compared to the corticosteroid group.
Another pivotal point of this study is the reduc-
tion of DAS28 and CDAI in RA and PsA groups. 
After the first injections we observed a significant 
reduction of DAS28 and CDAI, independent on 
the treatment. As far as CDAI was concerned, this 
reduction was even more evident. Indeed different 
from DAS28, CDAI does not consider acute phase 
reactants which are more strictly correlated to sys-
temic involvement rather than with monoarthritis. 
Moreover, a sub-analysis of RA patients with 
DAS28 ⩾2.6 showed that at week 4 anti-TNFα 
injection was able to significantly reduce DAS28 
values when compared to corticosteroid injected 
group. Conversely, no differences in DAS28 were 
observed in PsA group. All these data confirm that 
a tight control of the disease is important to achieve 
clinical remission (DAS28 <2.6) and we could 
Figure 5. Comparison between small and large joints at each time point according to the treatment arm for RA patients: (a) 
clinical outcomes, jVAS reduction; (b) clinical outcome, gVAS reduction; (c) US synovial membrane thickening score; (d) US joint 
effusion score; (e) PDUS score. Bars indicate mean ± SEM. ***P <0.001; **P <0.01; *P <0.05. CS, corticosteroids; gVAS, Visual 
Analogic Scale for global pain; jVAS, Visual Analogic Scale for involved joint pain; PD, power Doppler; TNFα, tumor necrosis factor 
α; US, ultrasonography.
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speculate that intra-articular anti-TNFα injections 
represent a powerful tool in a “treat-to-target” 
strategy. To note, in the 52-week follow-up period, 
no new flare of disease in the injected joint was 
observed in RA or PsA patients treated with intra-
articular anti-TNFα. On the contrary, in the RA 
and PsA group treated with intra-articular corticos-
teroids, five (24%) and seven (33%) new flares 
were recorded, respectively.
US and MRI score analysis further supported 
this hypothesis. In fact, a significant reduction of 
US synovial membrane thickening, joint effusion, 
and PDUS scores was achieved in RA and PsA 
patients treated with intra-articular anti-TNFα 
compared to patients treated with intra-articular 
corticosteroids. Of note, this significant reduction 
was more pronounced at week 4 and such improve-
ment was stable at each time point to week 12. In 
addition, an overall significant reduction of syno-
vitis score in RA patients treated with intra-articu-
lar anti-TNFα was found by MRI evaluation at 
week 12, mirroring the trend observed by US 
throughout the study. On this basis, we could pos-
tulate that intra-articular anti-TNF agents are more 
effective and faster to achieve a clinical and imag-
ing improvement in patients with RA and PsA.
Intra-articular anti-TNFα treatment displayed a 
systemic corticosteroid sparing activity within few 
weeks, thereby confirming the effectiveness of this 
approach. On the contrary, we were unable to dem-
onstrate any differences in NSAIDs patient self-
administration, probably because of other 
conditions or underlying articular disorders.52 
Finally we did not observe any relevant modifica-
tion in acute phase reactants, probably due to the 
administration route, suggesting that the effect of 
the therapies might be limited into the intra-articu-
lar space without any systemic effect. The intra-
articular half-life of corticosteroids and anti-TNFα 
agents is not known but we assume that anti-TNFα 
agents have a predominant local effect by binding 
a large amount of cytokines in the joint cavity 
before entering the bloodstream.53
Some authors demonstrated the improvement in 
both synovial thickness and expression of biologi-
cal markers in synovial tissue and synovial 
fluid,5,22,54,55 showing an effective biological role 
of intra-articular TNFα blockade. No data have 
been reported to elucidate the pharmacokinetics of 
anti-TNFα in the joint cavity; however, a more 
concentrated action of this drug may be assumed 
Figure 6. MRI of wrist joints of patients with RA injected 
with intra-articular anti-TNFα agent (a–d) or intra-articular 
corticosteroids (e–h). A reduction of synovitis is more 
pronounced in intra-articular anti-TNFα group (a, b, e, f: 
gradient echo STIR sequences without gadolinium contrast; c, 
d, g, h: gradient echo sequences with gadolinium contrast). RA 
MRI scores concerning synovitis (i) and bone edema (j). Bars 
in the line charts indicate mean ± SEM. Inside the box below 
the chart symbols refer to the comparison between each 
time point and the baseline according to the treatment arm 
(# P <0.05). *P <0.05 inside the chart refer to the comparison 
between the two treatment arms at the corresponding time 
point. CS, corticosteroids; MRI, magnetic resonance imaging; 
TNFα, tumor necrosis factor α.
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when delivered directly into the joint space. 
Moreover the different joints treated in this study 
display different anatomical and physiological fea-
tures that might influence the pharmacokinetics of 
the injected compounds. For example, after intra-
articular therapy in the knee, the drug rapidly dif-
fuses throughout the joint space while in the wrist, 
the drug might be compartmentalized.56 Although 
the number of recruited patients was limited, we 
tried to perform a subgroup analysis, according to 
the type of involved joint. Interestingly, in large 
joints the improvement of several outcomes was 
more evident than in small joints when treated with 
intra-articular anti-TNFα agents. We might sug-
gest that anatomical differences, a major amount of 
drug injected, or a different subjective perception 
of pain and discomfort in large joints, might explain 
these results.57
On these bases, many clinical and pharmacody-
namic variables might explain the discrepancy in 
the results observed in literature and mainly: (1) 
the amount of injected antibodies was not suffi-
cient to bind the majority of TNFα molecules pre-
sent in the synovial cavity; (2) antibodies injected 
into the joint neutralized only TNFα present in the 
synovial fluid, but did not penetrate into the syno-
vial tissue; (3) local processes supporting inflam-
mation within the joints were obviously not 
restricted to TNFα; (4) previous lack of response 
to steroid injection may be a predictor of lack of 
response to anti-TNFα factor injection; and (5) the 
IA injection not performed by US guidance mini-
mized the beneficial local effect of anti-TNFα 
agent.11,27,48,53 Larger studies specifically designed 
need to clarify these still open questions. We are 
aware that human anti-mouse antibodies and other 
neutralizing antibodies may cause acquired drug 
resistance to local anti-TNF agents as well as it 
was already described to systemic therapy. 
Similarly, the measurement of TNFα levels 
throughout the study period would help to better 
understand the disease course. Therefore larger 
studies including such evaluations would shed 
some light on different clinical outcomes.
The improvement in both articular and systemic 
outcomes, observed in our study, was independent 
by the type of anti-TNFα molecules used, although 
the small number of enrolled patients do not permit 
any definitive conclusions and analyses of larger 
cohort of patients need to clarify this therapeutic 
topic. We acknowledge that this study displays 
some limitations including the heterogeneity of 
involved joints and systemic treatment, the small 
number of patients studied in subgroup analyses, 
and MRI scans performed only in RA patients with 
a wrist or metacarpophalangeal joint arthritis. 
Moreover, we performed a 52-week follow-up to 
address safety and efficacy issues; however a 
longer follow-up period might be required to con-
firm our data.
During the past two decades, early and aggres-
sive treatment of RA and PsA with DMARDs has 
significantly reduced the effects of the disease in 
terms of joint damage and disability. Today, remis-
sion is an achievable goal in many patients, irre-
spective of the type of DMARD used, whether 
synthetic or biological. Our data provided the evi-
dence that US guided injection of intra-articular 
anti-TNFα agent injection is a safe and well toler-
ated procedure in both RA and PsA patients with 
monoarthritis, refractory to the treatment with sys-
temic anti-TNFα agent, combining the local and 
systemic effects of this class of molecules, to 
achieve a good clinical and radiological response 
and/or a DAS28 remission.
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